Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Safinamide

Brand: Xadago®
NICE TA: 
Indication: Treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of levodopa (L-dopa) alone or in combination with other PD medicinal products in mid to late stage fluctuating patients
Disease category: Central nervous system
Commissioning responsibility: CCG
PbR excluded: No

Background

Safinamide is not recommended for the treatment of patients with Parkinson’s disease. Evidence to support efficacy is not adequate to support a recommendation to prescribe.The drug is more expensive than others in its class and a favourable cost/benefit profile cannot be calculated for the drug.There are established options for treating patients at the late stage of their condition including two drugs currently supported that fall into the MAO‑B category.

Recommendation

LMMG recommendation: Black
Click here to find the definitions for the colour classifications

Reason for decision:  Not recommended for prescribing on the NHS in Lancashire

Supporting documents:

Safinamide New Medicine Recommendation (532.0 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Black

Black

Black

Black

Black

Black